Covid-19: Novavax delayed vaccine authorized in the United States
In these days the FDA cleared Novavax delayed vaccine in the United States for Covid-19. The vaccine will be a new opportunity for Americans to access vaccination as rates are at a standstill. Two years after the pandemic began and its development, the new vaccine has finally overcome its manufacturing problems, becoming the fourth vaccine to obtain authorization in the United States.
The CDC will meet next week to decide who will benefit from this vaccine. It is two-dose and was intended as a primary immunization rather than a booster. This is likely to limit its market. The Biden administration said it would purchase over 3.2 million doses for vaccinate over 1.6 million people.
Covid-19, Novavax’s fourth vaccine is coming to the United States
In announcing this purchase, the company stated that will finalize the necessary quality tests, a necessary step before the doses are released. Novavax hopes its vaccine will attract people who have repelled the shots from Pfizer-BioNTech and Moderna, who use messenger RNA technology. About 22% of people in the United States have not received a single dose of the Covid vaccine. The vaccine will work with two doses three weeks apart, but it works differently from m-RNA vaccines.
It provokes an immune response with nanoparticles made from surface proteins of the coronavirus that causes Covid-19. Similar protein-based vaccines have been used extensively around the world for decades. In Europe, only 12.6 million doses of Novavax were distributed between December, when the vaccine was authorized there, and June 30. In contrast, more than a billion doses of Pfizer-BioNTech and Moderna vaccines have been distributed in Europe. The clearance comes with the warning that Novavax’s vaccine is related to a high but low risk of cardiac inflammation known as myocarditis and pericarditis. In their review of Novavax’s data, the FDA scientists identified six cases of side effects in approximately 40,000 study volunteers.
In a series of clinical trials, Novavax found that its vaccine was highly protective against symptomatic infections. However, the original wording is probably not the same effective against the Omicron variant, which emerged in November and circumvented some of the protection afforded by other companies’ licensed vaccines. Novavax is developing new versions of its vaccine that target Omicron and its highly contagious sub-variants. Preliminary data from laboratory and animal studies indicate that a booster injection targeted to a previous Omicron sub-variant, BA.1, generates strong immune responses to the virus.
The company says it wants to accelerate his research on shots specifically made for two more recent versions of Omicron, known as BA.4 and BA.5. The company may then be able to attract vaccinated people who wish to switch to a new option to protect themselves from new variants.
Image by Alexandra_Koch from Pixabay